Deneysel Genetik Hayvan Modelleri
Özet
Nörolojik hastalıkların etiyolojisi, genetik, epigenetik ve çevresel faktörlerin etkileşimine dayanan karmaşık bir yapıya sahiptir. Bu hastalıkların moleküler mekanizmalarının anlaşılması için genetik olarak modifiye edilmiş hayvan modelleri önemli bir araştırma aracıdır. Alzheimer, Parkinson ve Huntington gibi nörodejeneratif bozuklukların yanı sıra çeşitli nöropsikiyatrik ve kalıtsal hastalıkların patofizyolojisi, transgenik, knockout ve knock-in modelleri kullanılarak hem hücresel hem de sistem düzeyinde incelenebilmektedir. Gelişmiş genetik mühendislik yöntemleri, özellikle CRISPR-Cas9 ve Cre/loxP sistemleri, hastalığa özgü mutasyonların yüksek hassasiyetle modellenmesine olanak tanımakta; böylece hastalıkların gelişim evreleri, dokuya özgü genetik etkiler ve gen-çevre etkileşimleri ayrıntılı biçimde araştırılabilmektedir. Hayvan modellerinin sınıflandırılması, doğal, indüklenmiş, genetik, negatif ve hibrit modeller gibi farklı kategorilere ayrılarak yapılmakta ve bu çeşitlilik araştırmacılara geniş bir deneysel seçenek sunmaktadır. Ancak doğru modelin seçilmesi, elde edilen bulguların bilimsel geçerliliği ve insan hastalıklarına aktarılabilirliği açısından kritik önem taşır. Model seçiminde araştırma amacı, patofizyolojik benzerlik, etik kurallar, tekrarlanabilirlik ve maliyet gibi faktörler dikkate alınmalıdır. Ayrıca 3R ilkeleri ve ARRIVE kılavuzları hem etik uyumun sağlanması hem de deneysel kalitenin artırılması için temel çerçeveler sunmaktadır. Son yıllarda, deneysel verilerin yeniden üretilebilirliğini artırmak için çevresel ve biyolojik heterojenitenin kontrollü şekilde deney tasarımlarına dahil edilmesi gerektiği yönünde görüşler güçlenmiştir. Genetik homojenlik avantaj sağlasa da, doğal popülasyonlardaki çeşitliliği tam olarak yansıtmayabilir; bu nedenle outbred hatların kontrollü kullanımı translasyonel değeri artırabilir. Genetik olarak modifiye edilmiş hayvan modelleri, hastalık mekanizmalarının aydınlatılmasından gen fonksiyonlarının belirlenmesine, biyobelirteç geliştirilmesinden gen terapisi stratejilerinin test edilmesine kadar geniş uygulama alanlarıyla biyomedikal araştırmaların temelini oluşturmaktadır. Bu yönleriyle, nörolojik ve genetik hastalıkların daha iyi anlaşılması ve yenilikçi tedavi stratejilerinin geliştirilmesinde vazgeçilmez bir araçtır.
The etiology of neurological diseases is characterized by a complex structure resulting from interactions among genetic, epigenetic, and environmental factors. Genetically modified animal models represent an essential research tool for elucidating the molecular mechanisms underlying these disorders. The pathophysiology of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, as well as various neuropsychiatric and inherited conditions, can be investigated at both cellular and systemic levels using transgenic, knockout, and knock-in models. Advanced genetic engineering technologies, particularly CRISPR-Cas9 and Cre/loxP systems, enable high-precision modeling of disease-specific mutations, allowing detailed investigation of disease progression, tissue-specific genetic effects, and gene–environment interactions. Animal models are classified into categories including spontaneous, induced, genetic, negative, and hybrid models, providing researchers with diverse experimental options. However, selecting an appropriate model is critical for ensuring scientific validity and translational relevance to human disease. Model selection should consider research objectives, pathophysiological similarity, ethical principles, reproducibility, and cost. In addition, the 3R principles and ARRIVE guidelines offer fundamental frameworks to ensure ethical compliance and improve experimental quality. Recently, increasing emphasis has been placed on incorporating controlled environmental and biological heterogeneity into experimental designs to enhance data reproducibility. Although genetic homogeneity offers experimental advantages, it may not adequately reflect natural population diversity; therefore, controlled use of outbred strains may improve translational value. Overall, genetically modified animal models underpin biomedical research, supporting applications from elucidating disease mechanisms and defining gene functions to biomarker development and evaluation of gene therapy strategies. Consequently, they remain indispensable for advancing understanding of neurological and genetic diseases and developing innovative therapeutic approaches.
Referanslar
Perše M. Animal models of human pathology: Revision, relevance and refinements. Biomedicines. 2024;12(11):2418.
Perlman RL. Mouse models of human disease: An evolutionary perspective. Evol Med Public Health. 2016;2016(1):170–176.
Davidson MK, Lindsey JR, Davis JK. Requirements and selection of an animal model. Isr J Med Sci. 1987;23(6):551–555.
Mukherjee P, Roy S, Ghosh D, et al. Role of animal models in biomedical research: A review. Lab Anim Res. 2022;38:18.
de Aguilar-Nascimento JE. Fundamental steps in experimental design for animal studies. Acta Cir Bras. 2005;20(1):2–8.
Wood MW, Hart LA. Selecting appropriate animal models and strains: Making the best use of research, information and outreach. AATEX. 2008;14(Special Issue):303–306.
Morrow PE, Haseman JK, Hobbs CH, et al. The maximum tolerated dose for inhalation bioassays: Toxicity vs overload. Fundam Appl Toxicol. 1996;29:155–167.
Wolfensohn S, Lloyd M, editors. Handbook of laboratory animal management and welfare. 3rd ed. Wiley-Blackwell; 2003.
Voelkl B, Altman NS, Forsman A, et al. Reproducibility of animal research in light of biological variation. Nat Rev Neurosci. 2020;21(7):394.
Baker M. 1,500 scientists lift the lid on reproducibility. Nature. 2016;533:452–454.
Voelkl B, Vogt L, Sena ES, et al. Reproducibility of preclinical animal research improves with heterogeneity of study samples. PLoS Biol. 2018;16(2):e2003693.
Festing MFW. Inbred strains should replace outbred stocks in toxicology, safety testing and drug development. Toxicol Pathol. 2014;42(4):701–709.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.
Dal Negro G, Sabbioni S, editors. Practical handbook on the 3Rs in the context of the Directive 2010/63/EU. European Commission; 2021.
Leist M, Hasiwa N, Rovida C, et al. Consensus report on the future of animal-free systemic toxicity testing. ALTEX. 2014;31(3):341–356.
van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245.
Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol. 2015;69:5.67.1–5.67.21.
Gurumurthy CB, Lloyd KCK. Generating mouse models for biomedical research: Technological advances. Dis Model Mech. 2019;12(1):dmm029462.
Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer’s disease. Mol Neurodegener. 2017;12:89.
Fowler T, Sen R, Roy AL. Regulation of primary response genes. Mol Cell. 2011;44(3):348–360.
Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014;32(4):347–355.
Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, et al. Animal models of cardiovascular diseases. J Biomed Biotechnol. 2011;2011:497841.
Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473–481.
Watters JW, McLeod HL. Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends Pharmacol Sci. 2003;24(2):55–58.
Franczyk B, Rysz J, Gluba-Brzózka A. Pharmacogenetics of drugs used in the treatment of cancers. Genes (Basel). 2022;13(2):311.
Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010;13(10):1161–1169.
Kim B, Kanai MI, Oh Y, et al. Response of the microbiome-gut-brain axis in Drosophila to amino acid deficit. Nature. 2021;593(7860):570–574.
Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240–2248.
Liu Y, Wang Y, Zhang X. Gene therapy for polygenic or complex diseases. Biomark Res. 2024;12(1):1–15.
Strome EM, Doudet DJ. Animal models of neurodegenerative disease: Insights from in vivo imaging studies. Mol Imaging Biol. 2007;9(4):186–195.
Tomioka I, Nagai Y, Seki K. Developing biomarkers for neurodegenerative diseases using genetically-modified common marmoset models. Neural Regen Res. 2018;13(7):1189–1190.
Doyle A, McGarry MP, Lee NA, Lee JJ. The construction of transgenic and gene knockout/knockin mouse models of human disease. Transgenic Res. 2012;21(2):327–349.
Bedell MA, Jenkins NA, Copeland NG. Mouse models of human disease. Part I: Techniques and resources for genetic analysis in mice. Genes Dev. 1997;11(1):1–10.
Hardouin SN, Nagy A. Mouse models for human disease. Clin Genet. 2000;57(4):237–244.
Rosenthal N, Brown S. The mouse ascending: Perspectives for human-disease models. Nat Cell Biol. 2007;9(9):993–999.
Kühn R, Wurst W. Mouse mutagenesis and gene function. In: Model Organisms: Functional and Comparative Genomics (Specialist Review). 2005.
Zhou J, Liang S, Yin L, et al. Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency. Mol Ther. 2025;33(3):1197–1212.
Yu Y, Bradley A. Engineering chromosomal rearrangements in mice. Nat Rev Genet. 2001;2(10):780–790.
Lee H, Yoon DE, Kim K. Genome editing methods in animal models. Anim Cells Syst. 2020;24(1):8–16.
Lin Y, Li J, Li C, et al. Application of CRISPR/Cas9 system in establishing large animal models. Front Cell Dev Biol. 2022;10:919155.
Weiss AR, Liguore WA, Brandon K, et al. A novel rhesus macaque model of Huntington's disease recapitulates key neuropathological changes along with motor and cognitive decline. eLife. 2022;11:e77568.
Howland DS, Munoz-Sanjuan I. Mind the gap: Models in multiple species needed for therapeutic development in Huntington's disease. Mov Disord. 2014;29(11):1397–1403.
Nystuen KL, McNamee SM, Akula M, et al. Alzheimer's disease: Models and molecular mechanisms informing disease and treatments. Bioengineering. 2024;11(1):45.
Calabresi P, Mechelli A, Natale G, et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.
Lee H. Genetically engineered mouse models for drug development and preclinical trials. Biomol Ther. 2014;22(4):267–274.
Kim WY, Sharpless NE. Drug efficacy testing in mice. Curr Top Microbiol Immunol. 2012;355:19–38.
Ghanemi A, Yoshioka M, St-Amand J. Obese animals as models for numerous diseases: Advantages and applications. Medicina (Kaunas). 2021;57(5):399.
Wong SK, Chin KY, Suhaimi FH, Fairus A, Ima-Nirwana S. Animal models of metabolic syndrome: A review. Nutr Metab (Lond). 2016;13:65.
Hartung T. The (misleading) role of animal models in drug development. Front Drug Discov. 2024;8:1355044.
Ormandy EH, Dale J, Griffin G. Genetic engineering of animals: Ethical issues, including welfare concerns. Can Vet J. 2011;52(5):544–550.
Shakweer WME, Krivoruchko AY, Dessouki SM, et al. A review of transgenic animal techniques and their applications. J Genet Eng Biotechnol. 2023;21(1):55.
Greek R, Menache A. Systematic reviews of animal models: Methodology versus epistemology. Int J Med Sci. 2013;10(3):206–221.
